Factors that affect the false negative rate of sentinel lymph node mapping with methylene blue dye alone in breast cancer

Li Huang1,2, Jun Zhang1, Zhi-Cheng Ge1 and Xiang Qu1

Abstract

Objective: This study aimed to investigate the clinicopathological factors of the false negative rate (FNR) and accuracy of sentinel lymph node biopsy (SLNB) mapping with 1% methylene blue dye (MBD) alone, and to examine how to reduce the FNR in patients with breast cancer.

Methods: A total of 365 patients with invasive breast carcinoma who received axillary lymph node dissection after SLNB were retrospectively analyzed. SLNB was performed with 2 to 5 mL of 1% MBD. We studied the clinicopathological factors that could affect the FNR of SLNB.

Results: The identification rate of sentinel lymph nodes (SLNs) was 98.3% (359/365) and the FNR of SLNB was 10.4% (16/154). Multivariate analysis showed that the number of dissected SLNs and metastatic lymph nodes were independent predictive factors for the FNR of SLNB. The FNR in patients with 1, 2, 3, and ≥4 SLNs was 23.53%, 15.79%, 3.85%, and 1.79%, respectively.

Conclusions: SLNB mapping with MBD alone in patients with breast cancer can produce favorable identification rates. The FNR of SLNB decreases as the number of SLNs rises. Because of side effects of searching for additional SLNs and the FNR, removal of three or four SLNs may be appropriate.

1Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
2Department of Breast Surgery Ward No. 3, The Affiliated Tumor Hospital of Shanxi Medical University, Shanxi Tumor Hospital, Taiyuan, Shanxi, China

Corresponding author:
Zhi-Cheng Ge, Department of general surgery, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Beijing 100050, China.
Email: gezhicheng2000@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Breast neoplasm, false negative rate (FNR), sentinel lymph node biopsy (SLNB), methylene blue, metastasis, axillary lymph node dissection

Date received: 30 September 2018; accepted: 9 January 2019

Background

Breast cancer is listed is the most common malignant tumor worldwide. The incidence of breast cancer has increased over the last 30 years. The age standardized incidence rate of breast cancer in China has reached 23.2/100,000, and the age standardized death rate of breast cancer in China has approached 4.9/100,000.\(^1\) Axillary lymph node (ALN) metastasis is an important indicator for deciding on the prognosis and treatment for patients with breast cancer. When a patient with invasive breast cancer is treated surgically, axillary lymph node dissection (ALND) is a critical procedure of the treatment and it is also the most accurate technique for assessing the metastasis status of axillary lymph nodes (ALNs). However, ALND can lead to postoperative morbidities, such as sensory loss, lymphedema, seroma formation, and limited mobility. This worsens the patients’ quality of life and results in pain. Higher awareness of breast cancer prevention and new methods of treatment lead to a higher proportion of early-stage patients. The tumor burden of regional lymph nodes has also been reduced,\(^2,3\) which reduces the number of patients who require axillary surgery. In the 1990s, ALND was replaced by a new technique termed sentinel lymph node biopsy (SLNB) in breast cancer, and the guidance measure of “axillary-conserving” was taken.

SLNs are the first lymph nodes that receive lymphatic drainage from a tumor. Theoretically, they are also the first lymphatic sites of metastasis. SLN-negative patients can avoid ALND, which can reduce the incidence of complications of ALND and does not increase the risk of axillary recurrence.\(^4,5\) However, surgeons and patients are still concerned about the false negative results when performing SLNB instead of ALND. A higher false negative rate (FNR) leads to a physical and psychological burden for patients, which greatly restricts the popularity of SLNB. Consequently, an increasing amount of studies are being undertaken to minimize the FNR of SLNB as much as possible.\(^6,7\)

There are three common mapping methods for SLNB in breast cancer, including the use of blue dye tracer (e.g., isosulfan blue, methylene blue, and patent blue dye), use of radioisotope tracer, and dual staining of blue dye combined with a radioisotope.\(^8,9\) Previous studies have successfully applied 1% methylene blue dye (MBD) in SLNB for breast cancer.\(^10^-18\) However, several studies have reported that the combination method of blue dye with radioisotopes is much better than blue dye alone for identification of SLNs.\(^19^-21\) Unfortunately, this method is costly and rarely adopted in China because many hospitals currently have no qualifications to provide radionuclide drugs and instruments.\(^22\) MBD overcomes the restriction of radionuclide imaging with specialized equipment in primary hospitals, and also overcomes the disadvantages of the expensive price and difficult source of patent blue and isosulfan...
blue. At present, a hierarchical medical system has been set up to improve services at county and township-level health centers, especially in less developed areas in China. Because of this hierarchical medical system, an increasing number of patients with early-stage breast cancer are confined to primary hospitals for treatment in less developed areas. Based on the advantages of MBD, it has been the only option for localizing SLNs in primary hospitals in China. This study aimed to investigate the identification rate and the FNR by applying 1% MBD alone to map SLNs, and to examine the clinicopathological factors affecting the FNR of SLNB.

**Methods**

**Patients**

In our study, female patients with early breast cancer were retrospectively enrolled during January 2009 to December 2012 in Beijing Friendship Hospital. Four surgeons (ZCG, XQ, JZ, and LH) participated in this research. GZC, QX, and ZJ have more than 10 years and LH has more than 8 years of experience in performing breast cancer surgery.

The inclusion criteria were as follows: (i) the patient had primary breast cancer; (ii) cN0 cases were confirmed through axillary palpation and imaging examinations, such as mammography or a breast ultrasound examination; (iii) the patient had no history of axillary surgery or radiotherapy; (iv) the patient had no preoperative chemotherapy; and (v) the patient agreed to undergo ALND after SLNB. The exclusion criteria were as follows: (i) the patient had a history of axillary surgery; (ii) the patient had breast cancer in her pregnancy or lactation; (iii) the patient had a history of neoadjuvant chemotherapy or radiotherapy; and (iv) the pathological type was ductal carcinoma in situ.

This study was approved by the Ethics Committee of Beijing Friendship Hospital and all patients signed an informed consent form.

**Surgical procedure and pathological evaluation**

Lymphatic mapping for tracing SLNs was performed using 1% MBD. After successful anesthesia, 2 to 5 mL of MBD was injected into the subareolar area, after which the breast was massaged for 10 minutes. Blue nodes or lymph nodes with lymphatic blue channels were identified as sentinel nodes. The procedure of ALND was performed at levels I to II. When suspicious lymph node metastases were found at level II, then ALND was continued at level III. Slices of nodes were parallel to the longitudinal axis and were not thicker than 2 mm. Intraoperative frozen section analyses was routinely performed for every harvested SLN, which was classified into negative or positive for metastases. Furthermore, all nodes were formalin fixed and embedded in paraffin. Sections were stained with hematoxylin–eosin postoperatively. Sentinel node metastases were classified according to the American Joint Committee on Cancer as isolated tumor cells (cell clusters or a single cell no larger than 0.2 mm), micro-metastasis (tumor deposits between 0.2 and 2.0 mm), and macro-metastasis (tumor deposits > 2 mm). The tumors were classified according to the World Health Organization Histological Classification of Breast Cancers, and grading was defined by reference to Elston and Ellis modification. Invasive breast cancer was classified by the 2013 St. Gallen Consensus, and was divided into molecular subtypes as follows. A luminal A-like tumor was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative, with Ki-67 expression < 14% and high progesterone.
receptor (PR) levels (≥20%). A luminal B-like HER2-negative tumor was ER-positive and HER2-negative, with Ki-67 expression ≥14% and low PR levels (<20%). A luminal B-like HER2-positive tumor was ER-positive and HER2-positive. An HER2-positive tumor was HER2-positive, PR-negative, and ER-negative. A triple-negative tumor was HER2-negative, PR-negative, and ER-negative.

**Adjuvant therapy**

All participants were treated in compliance with National Comprehensive Cancer Network Guidelines. Patients with breast conservation surgery or positive lymph nodes were treated by radiotherapy. Taxanes and anthracyclines were used in chemotherapy regimens. Aromatase inhibitors and tamoxifen were used in hormone therapy. HER-2-positive patients were treated with adjuvant trastuzumab therapy.

**Statistical analysis**

SPSS 19.0 for Windows (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Fisher’s exact test and the chi square test were used for group comparisons. Risk factors for the FNR and accuracy rate in SLNB were evaluated with logistic regression analysis. A P value < 0.05 was considered statistically significant. Evaluation of results was performed by the SLNB technical standard of Louisville University. The degree of metastasis was calculated as the number of metastatic lymph nodes divided by the number of lymph nodes and then multiplied by 100%. The identification rate was calculated as the number of identified SLNs divided by the number of patients with the treatment of SLNB and then multiplied by 100%. The FNR was calculated as the number of false negative cases divided by the number of false negative plus true positive cases and then multiplied by 100%. Sensitivity was calculated as the number of true positive cases divided by the number of false negative plus true positive cases and then multiplied by 100%. The accuracy rate was calculated as the number of true positive plus true negative cases divided by the number of patients with the treatment of SLNB and then multiplied by 100%. The negative predictive value was calculated as the number of true negative cases divided by the number of false negative plus true negative cases and then multiplied by 100%.

**Results**

**Patients’ characteristics**

We reviewed 365 patients from January 2009 and December 2012, but SLNs could not be found in six patients. The final analysis included 359 patients. The patients’ clinico-pathological characteristics are shown in Table 1. The mean (±standard deviation) age of the patients was 54.97 ± 11.09 years old (range, 30–83 years old). The mean size of pathological tumors was 2.53 ± 1.28 cm (range, 0.6–5.0 cm). The diagnoses included 333 patients with invasive ductal carcinoma, 14 with invasive lobular carcinoma, six with invasive papillary carcinoma, and six with mucinous carcinoma. The molecular subtypes are shown in Table 1. A total of 250 (69.6%) patients received breast-conserving surgery and 109 (30.4%) received mastectomy. No skin necrosis was observed, but blue tattooing of the skin was found in 30 patients. No patients had systemic anaphylactic reactions.

**Identification of SLNs using 1% MBD and mapping of axillary SLNs**

Of the 365 patients, 359 had SLNs, with an identification rate of 98.3% (359/365).
Of these 359 patients, 154 (42.9%) had ALN metastasis and 205 (57.1%) were without ALN metastasis. Among 154 patients with ALN metastases, SN metastases were negative in 16 patients, with an FNR of 10.4% (16/154). The accuracy rate was 95.6% (343/359), the negative predictive value was 92.8% (205/221), and the specificity was 100% (205/205). The number of dissected SLNs for 359 patients was 1125, and the mean number of SLNs was 3.13 \pm 1.98 \text{ (range, 1–10)} (Table 2). The number of SLN metastases was 196 and the degree of metastasis was 17.42% (196/1125). Only one sentinel lymph node was dissected in 80 patients. A total of 34 of these patients developed ALN metastasis, of whom 12 patients developed SLN

**Table 1. Tumor pathology and patients’ characteristics.**

| Characteristics                        | Number of patients (%) |
|----------------------------------------|------------------------|
| Age, years                             |                        |
| ≤40                                    | 33 (9.2)               |
| >40                                    | 326 (90.8)             |
| Menstruation status                    |                        |
| Premenopause                           | 135 (37.6)             |
| Postmenopause                          | 224 (62.4)             |
| Body mass index, kg/m²                 |                        |
| <30                                    | 321 (89.4)             |
| ≥30                                    | 38 (10.6)              |
| Tumor location                         |                        |
| Outer upper quadrant                   | 173 (48.2)             |
| Inner upper quadrant                   | 95 (26.5)              |
| Outer lower quadrant                   | 50 (13.9)              |
| Inner lower quadrant                   | 32 (8.9)               |
| Central region                         | 9 (2.5)                |
| Side of the tumor                      |                        |
| Left                                   | 183 (50.9)             |
| Right                                  | 176 (49.1)             |
| Pathological type                      |                        |
| IDC                                    | 333 (92.7)             |
| ILC                                    | 14 (3.9)               |
| Mucous carcinoma                       | 6 (1.7)                |
| Other                                  | 6 (1.7)                |
| Tumor size (mm)                        |                        |
| <20                                    | 195 (54.3)             |
| ≥20 and ≤50                            | 162 (45.1)             |
| >50                                    | 2 (0.6)                |
| Estrogen receptor                      |                        |
| Positive                               | 270 (75.2)             |
| Negative                               | 89 (24.8)              |
| Progesterone receptor                  |                        |
| Positive                               | 232 (64.6)             |
| Negative                               | 127 (35.4)             |
| Ki-67 expression levels                |                        |
| <14%                                   | 57 (15.9)              |
| ≥14%                                   | 302 (84.1)             |
| HER2 state                             |                        |
| Positive                               | 143 (39.8)             |
| Negative                               | 216 (60.2)             |
| Histological grade                     |                        |
| I                                      | 46 (12.8)              |
| II                                     | 249 (69.4)             |
| III                                    | 64 (17.8)              |

**Table 1. Continued.**

| Characteristics                        | Number of patients (%) |
|----------------------------------------|------------------------|
| Lymphovascular invasion                |                        |
| Present                                | 28 (7.8)               |
| Absent                                 | 331 (92.2)             |
| Multifocality                          |                        |
| Multifocal                             | 19 (5.3)               |
| Unifocal                               | 340 (94.7)             |
| Molecular subtypes                     |                        |
| Luminal A                               | 49 (13.6)              |
| Luminal B                               | 220 (61.3)             |
| HER2 positive                           | 51 (14.2)              |
| Triple negative                         | 39 (10.9)              |
| Number of dissected SLNs               |                        |
| 1                                      | 80 (22.2)              |
| 2                                      | 88 (24.5)              |
| 3                                      | 62 (17.4)              |
| ≥4                                     | 129 (35.9)             |
| Number of metastatic lymph nodes       |                        |
| 0                                      | 205 (57.2)             |
| ≤3                                     | 119 (33.1)             |
| ≥4 and ≤9                              | 26 (7.2)               |
| ≥10                                    | 9 (2.5)                |

ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor 2; SLNs, sentinel lymph nodes.
and non-SLN metastasis, eight patients developed non-SLN metastasis with SLN-negative, and 14 developed SLN metastasis with non-SLN negative. A total of 46 of these patients did not develop SLN and non-SLN metastasis. Two sentinel lymph nodes were dissected in 88 patients. Among these patients, 38 developed ALN metastasis. Furthermore, 15 patients developed SLN and non-SLN metastasis, six developed non-SLN metastasis with SLN-negative, and 17 developed SLN metastasis with non-SLN negative. A total of 50 of these patients did not develop SLN and non-SLN metastasis. Three sentinel lymph nodes were dissected in 62 patients. A total of 26 of these patients developed ALN metastasis. Among these patients, 10 developed SLN and non-SLN metastasis, one developed non-SLN metastasis with SLN-negative, and 15 developed SLN metastasis with non-SLN negative. A total of 36 of these patients did not develop SLN and non-SLN metastasis. Four sentinel lymph nodes were dissected in 129 patients. A total of 56 of these patients developed ALN metastasis. Among these patients, 13 developed SLN and non-SLN metastasis, one developed non-SLN metastasis with SLN-negative, and 42 developed SLN metastasis with non-SLN negative. A total of 73 of these patients did not develop SLN and non-SLN metastasis. The number of dissected non-SLNs in all of the 359 patients was 5078, and the mean number of dissected non-SLNs was 14.14 ± 5.64 (range, 6–30). The total number of non-SLN metastasis was 259 and the degree of metastasis was 5.1% (260/5078).

**Association between the FNR and accuracy rate of SLNB and clinicopathological features**

In univariate analysis, the accuracy rate and FNR of SLNB were not significantly associated with factors, such as body mass index, age, tumor location, pathological type, histological classification, molecular subtype, ER state, PR state, HER2 state, menstruation status, Ki-67 protein levels, or other relevant factors (Table 3). The FNR of SLNB was significantly associated with tumor size (P = 0.048), the number of dissected SLNs (P = 0.005), and the number of metastatic lymph nodes (P = 0.001).

In multivariate analysis, the number of dissected SLNs (P = 0.005) and metastatic lymph nodes (P = 0.022) still remained significant independent risk factors for the FNR (adjusted odds ratio of 0.461 [95% confidence interval, 0.269 to 0.790], 2.801 [95% confidence interval, 1.159 to 6.771], respectively) (Table 4).

**Discussion**

Management of early breast cancer has shifted over time to conservative treatment. ALND has been replaced by SLNB for judging axillary staging.27,28 Large-sample, prospective, randomized, controlled trials, such as the ALMANAC, SNB-185, and NSABP B-32 studies, showed that SLNB could accurately predict ALN staging.29–31 Previous studies showed that differences in overall survival, disease-free survival, and recurrence-free survival between the only SLNB group and ALND group for SLN-negative patients with breast cancer were

| SLN status | Non-SLN status | Total |
|------------|----------------|-------|
| (+)        | 50 88          | 138   |
| (−)        | 16 205         | 221   |
| Total      | 66 293         | 359   |

SLN, sentinel lymph node; ALN, axillary lymph node; non-SLN, non-sentinel lymph node; SLNB, sentinel lymph node biopsy.
Table 3. Comparison of clinicopathological characteristics between the FNR and accuracy rate for SLNB.

| Characteristic                      | n   | FNR (%) | n   | Accuracy rate (%) | \( \chi^2 \) | P     |
|------------------------------------|-----|---------|-----|-------------------|-------------|-------|
| Age, years                         |     |         |     |                   |             |       |
| ≤40                                | 1   | 8.33    | 32  | 96.97             | 0.000       | 1.000 |
| >40                                | 15  | 10.56   | 311 | 95.40             |             |       |
| Menstruation status                |     |         |     |                   |             |       |
| Premenopause                       | 5   | 8.62    | 130 | 96.30             | 0.288       | 0.591 |
| Postmenopause                      | 11  | 11.46   | 213 | 95.09             |             |       |
| Body mass index (kg/m\(^2\))      |     |         |     |                   |             |       |
| <30                                | 14  | 10.00   | 307 | 95.64             | 0.000       | 1.000 |
| ≥30                                | 2   | 14.29   | 36  | 94.74             |             |       |
| Tumor location                     |     |         |     |                   |             |       |
| Outer upper quadrant               | 9   | 10.98   | 164 | 94.80             | 0.436       | 0.509 |
| Other                              | 7   | 9.72    | 179 | 96.24             |             |       |
| Side of the tumor                  |     |         |     |                   | 1.217       | 0.270 |
| Left                               | 6   | 7.32    | 177 | 96.72             |             |       |
| Right                              | 10  | 13.9    | 166 | 94.5              |             |       |
| Pathological type                  |     |         |     |                   |             |       |
| IDC                                | 14  | 10.00   | 319 | 95.80             | –           | 0.325 |
| ILC                                | 1   | 16.67   | 13  | 92.86             |             |       |
| Other                              | 1   | 12.50   | 11  | 91.67             |             |       |
| Tumor size (mm)                    |     |         |     |                   | 3.913       | 0.048 |
| ≤20                                | 14  | 16.87   | 217 | 93.94             |             |       |
| >20                                | 2   | 2.82    | 126 | 98.44             |             |       |
| Estrogen receptor                  |     |         |     |                   | 0.076       | 0.782 |
| Negative                           | 3   | 11.11   | 86  | 96.63             |             |       |
| Positive                           | 13  | 10.24   | 257 | 95.19             |             |       |
| Progesterone receptor              |     |         |     |                   | 0.789       | 0.375 |
| Negative                           | 4   | 10.00   | 123 | 96.85             |             |       |
| Positive                           | 12  | 10.53   | 220 | 94.83             |             |       |
| Ki-67 expression levels            |     |         |     |                   | 0.530       | 0.467 |
| <14%                               | 1   | 3.26    | 56  | 98.25             |             |       |
| ≥14%                               | 15  | 12.19   | 287 | 95.03             |             |       |
| HER2 state                         |     |         |     |                   | 0.722       | 0.395 |
| Positive                           | 8   | 10.26   | 135 | 94.41             |             |       |
| Negative                           | 8   | 10.53   | 208 | 96.29             |             |       |
| Histological grade                 |     |         |     |                   | 0.772       | 0.680 |
| I                                  | 1   | 5.26    | 45  | 97.82             |             |       |
| II                                 | 12  | 11.88   | 237 | 95.18             |             |       |
| III                                | 3   | 8.82    | 61  | 95.31             |             |       |
| Lymphovascular invasion            |     |         |     |                   | 1.426       | 0.232 |
| Present                            | 3   | 15.79   | 25  | 89.29             |             |       |
| Absent                             | 13  | 9.5     | 318 | 96.07             |             |       |
| Multifocality                      |     |         |     |                   | –           | 0.589 |
| Multifocal                         | 1   | 9.09    | 18  | 94.74             |             |       |
| Unifocal                           | 15  | 10.34   | 325 | 95.59             |             |       |

(continued)
significant. However, SLNB instead of ALND is based on a lower false negative rate. The method for mapping SLNs in breast cancer is one of the main factors affecting the identification rate and FNR. The technique of dual localization with a radioisotope and blue dye is effective for mapping of SLNs, and the FNR is 5% to 10%. After 24 studies were reviewed systematically, the authors found that the combination of a radioisotope with blue dye resulted in a higher identification rate than that for applying radioisotope alone, but the FNR was not significantly reduced. The technique of dual localization with a radioisotope and blue dye is most widely used and is considered as the standard technology for localization of SLNs.

Nevertheless, many primary hospitals in China have the obstacle of limited access to patent blue dye, radioisotope tracers, isosulfan blue, and nuclear medicine facilities. Owing to a detection rate of approximately 90.82% to 98.06%, blue dye staining is currently more extensively applied in China. Furthermore, the problem of limited access to patent blue dye was successfully resolved with application of 1% MBD by some researchers. A previous study showed MBD had the same effects as did isosulfan blue dye when used for identifying SLNs. MBD is cheaper and easier to obtain in many primary hospitals in China and is not related to allergic reactions that are potentially life-threatening. For pregnant patients, applying MBD for mapping

| Characteristic                          | n   | FNR (%) | Accuracy rate (%) | $\chi^2$ | P   |
|----------------------------------------|-----|---------|-------------------|---------|-----|
| Molecular subtypes                     |     |         |                   |         |     |
| Luminal A                              | 1   | 4.17    | 48                | 97.95   |     |
| Luminal B                              | 12  | 11.88   | 208               | 94.55   |     |
| HER2 positive                          | 3   | 17.65   | 48                | 94.12   |     |
| Triple negative                        | 0   | 0       | 39                | 100     |     |
| Number of dissected SLNs               |     |         |                   |         |     |
| 1                                      | 8   | 23.53   | 72                | 90.00   |     |
| 2                                      | 6   | 15.79   | 82                | 93.18   |     |
| 3                                      | 1   | 3.85    | 61                | 98.39   |     |
| $\geq 4$                               | 1   | 1.79    | 128               | 99.22   |     |
| Number of metastatic lymph nodes       |     |         |                   |         |     |
| $\leq 3$                               | 10  | 8.26    | 316               | 96.93   |     |
| $\geq 4$ and $\leq 9$                  | 6   | 25.0    | 19                | 76.0    |     |
| $\geq 10$                              | 0   | 0       | 8                 | 100     |     |

*Fisher’s exact test. FNR, false negative rate; SLNB, sentinel lymph node biopsy; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor 2; SLNs, sentinel lymph nodes.

**Table 4. Multivariate analysis for risk factors of the false negative rate in sentinel lymph node biopsy.**

| Variables                            | Odds ratio | 95% CI   | P   |
|--------------------------------------|------------|----------|-----|
| Number of metastatic lymph nodes     | 2.801      | 1.159–6.771 | 0.022 |
| Number of dissected SLNs             | 0.461      | 0.269–0.790 | 0.005 |
| Tumor size                           | 0.223      | 0.047–1.050 | 0.058 |

CI, confidence interval; SLNs, sentinel lymph nodes.
SLNs is safe.\textsuperscript{38} Because of the hierarchical medical in China, MBD alone is widely used for localizing SLNs in primary hospitals. A recent meta-analysis by Li et al.\textsuperscript{39} concluded that MBD alone for mapping SLNs leads to a better identification rate of 91%, but a higher FNR of 13% according to criteria recommended by the American Society of Breast Surgeons. Therefore, we attempted to only apply 1% MBD for identification of SLNs. To further reduce the FNR of SLNB, related factors need to be comprehensively analyzed.

The American Society of Clinical Oncology reported the results of six trials on SLNB, and their FNRs ranged from 4.6\% to 16.7\%,\textsuperscript{40,41} with an average of 8.4\% overall.\textsuperscript{30} The American Society of Breast Surgeons formed a team to establish standards for SLNB. This team suggested in 2000 that the SLNB identification rate should be equal to or higher than 85\% and that the FNR should be equal to or lower than 5\%.\textsuperscript{43}

The identification rate of SLNB in our study was 98.3\% and the FNR was 10.4\%, which are consistent with most previous reports.\textsuperscript{10,11} In our study, univariate analysis showed that the FNR and the accuracy of SLNB were related to the size of the tumor, which is consistent with conclusions drawn by many scholars.\textsuperscript{43–45} The lymphatic metastasis rate rises in large volume tumors. Lymphatic channels are often clogged by metastatic cancer cells, which leads to a change in the original lymphatic circulation and the imaging agent or radionuclide in the lymphatic vessels is impeded for normal transfer.\textsuperscript{33} Moreover, metastatic tumor cells invade SLN for a long time, which leads to a reduction of antigen-induced lymphocyte induction and a decrease in the ability of macrophages to absorb tracers. However, replacement lymph nodes with absorption tracers do not accurately reflect the ALN status.\textsuperscript{46} Multivariate analysis in our study showed that the size of the tumor was not related to the FNR of SLNB, which is similar to the findings of Wong et al.\textsuperscript{47} This result may be related to the low numbers of participants in this study.

In our study, the number of dissected SLNs was a significant risk factor for the FNR, which is consistent with many studies. Chok et al.\textsuperscript{48} found that the FNR of SLNB significantly decreased with an increased number of dissected SLNs (P < 0.009). Goyal et al.\textsuperscript{33} found that in patients with one dissected SLN and more than two dissected SLNs, the FNR of SLNB was 10.1\% and 1.1\%, respectively (P = 0.010). Yi et al.\textsuperscript{49} reported that > 99\% of positive SLNs were discovered when the number of dissected SLNs was up to five. In the present study, the patients were classified according to the number of dissected SLNs into four groups (1, 2, 3, and ≥4 SLNs). The FNR of each group was 23.53\%, 15.79\%, 3.85\%, and 1.79\%, respectively, with a significant difference among the groups. We found that the FNR of SLNB decreased with an increase in the number of SLNs (P = 0.005). When the numbers of dissected SLNs was more than more, the FNR was 1.79\%, and the accuracy rate reached 99.2\%, which indicated that more than 99\% positive SLNs could be found and the FNR of SLN was significantly reduced. Therefore, for patients with a fewer number of detected SLNs, SLNB is a great risk to replace ALND. However, the number of dissected SLNs affects not only FNR results, but also the morbidity of the SLNB procedure.\textsuperscript{42,50}

For patients with > four dissected SLNs, the status of axillary lymph nodes can be predicted by SLNB. Approximately 99\% of nodal-positive patients are confirmed by removing four SLNs, and thus the benefits of searching for additional SLNs are minimal.\textsuperscript{49,51} On the basis of a FNR ≤ 5\%\textsuperscript{42} and the side effects of searching for additional SLNs, we suggest that the
appropriate number of removed SLNs is three to four when applying MBD alone.

The differences in the FNR reported worldwide may be related to the proficiency of surgeons. The experience and proficiency level of surgeons greatly affect the accurate localization of SLNs, especially when blue dye is the only choice as the tracer. Cox et al.\textsuperscript{52} thought that to ensure high accuracy, surgeons should be asked to perform 20 surgeries at least independently. Snider et al.\textsuperscript{53} thought that surgeons should independently perform operations in 45 cases. The surgeons in the present study have approximately 8 to 10 years of experience of SLNB, and have completed hundreds of these procedures every year. Therefore, effective measures for reducing the FNR of SLNB are strictly selecting the indications, standardizing the operation standards, and improving the operation proficiency of the surgeons.

Limitations of this study are that this was a single-center study and a relatively small number of participants were included. Therefore, multicenter studies with large sample sizes are required for further validation.

**Conclusions**

This study validates the accuracy and feasibility of SLNB mapping with MBD alone. However, the following factors should be taken into account in clinical practice. First, surgeons should take care when only blue nodes are found in patients with large tumors. When applying MBD alone, surgeons should keep searching for suspicious non-blue lymph nodes to eliminate false negative possibilities. Second, the number of removed SLNs needs to be increased to reduce the FNR. The FNR is $\leq5\%$ when the number of removed SLNs is three to four. However, the number of removed SLNs not only affects FNR results, but also affects the morbidity of the SLNB procedure. Therefore, we suggest that the appropriate number of removed SLNs should be three to four when applying MBD alone in SLNB. Third, the operation level and proficiency of the surgeons should be improved as much as possible to reduce the FNR.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Li Huang \(\text{http://orcid.org/0000-0001-6565-0782}\)

**References**

1. Chen W, Zheng R, Zeng H, et al. The updated incidences and mortalities of major cancers in China, 2011. *Chin J Cancer* 2015; 34: 502–507.
2. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. *Ann Surg* 2010; 252: 426–433.
3. Andersson Y, de Boniface J, Jönsson PE, et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. *Br J Surg* 2012; 99: 226–231.
4. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National surgical adjuvant breast and bowel project phase III protocol B-32. *J Clin Oncol* 2010; 28: 3929–3936.
5. Pepels MJ, Vestjens JH and de Boer M. Safety of avoiding routine use of axillary
dissection in early stage breast cancer: a systematic review. *Breast Cancer Res Treat* 2011; 125: 301–313.

6. Jakobsen JK. Sentinel node biopsy in uro-oncology: a history of the development of a promising concept. *Urol Oncol* 2015; 33: 486–493.

7. James TA, Coffman AR, Chagpar AB, et al. Troubleshooting sentinel lymph node biopsy in breast cancer surgery. *Am Surg Oncol* 2016; 23: 3459–3466.

8. Wada N, Imoto S, Yamauchi C et al. Correlation between concordance of tracers, order of harvest, and presence of metastases in sentinel lymph nodes with breast cancer. *Am Surg Oncol* 2005; 12: 497–503.

9. Aoyama K, Kamio T, Ohchi T et al. Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green. *World J Surg Oncol* 2011; 9: 157.

10. Simmons RM, Smith SMR and Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. *Breast J* 2001; 7: 181–183.

11. Simmons R, Thevarajah S, Brennan MB, et al. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. *Am Surg Oncol* 2003; 10: 242–247.

12. Varghese P, Mostafa A, Abdel-Rahman AT, et al. Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. *Eur J Surg Oncol* 2007; 33: 147–152.

13. Blessing WD, Stolier AJ, Teng SC, et al. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. *Am J Surg* 2002; 184: 341–345.

14. Zakaria S, Hoskin TL and Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. *Am J Surg* 2008; 196: 228–233.

15. Mathelin C, Croce S, Brasse D, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. *Cancer Res* 2009; 29: 4119–4126.

16. Nour A. Efficacy of methylene blue dye in localization of sentinel lymph node in breast cancer patients. *Breast J* 2004; 10: 388–391.

17. Golshan M and Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? *Breast J* 2006; 12: 428–430.

18. Thevarajah S, Huston TL and Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. *Am J Surg* 2005; 189: 236–239.

19. Radovanovic Z, Golubovic A, Plzak A, et al. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. *Eur J Surg Oncol* 2004; 30: 913–917.

20. Syme DB, Collins JP and Mann GB. Comparison of blue dye and isotope with blue dye alone in breast sentinel node biopsy. *ANZ J Surg* 2005; 75: 817–821.

21. Hung WK, Chan CM, Ying M, et al. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. *Br J Surg* 2005; 92: 1494–1497.

22. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. *J Clin Oncol* 2000; 18: 2560–2566.

23. Edge S, Byrd DR and Compton CC. *AJCC cancer staging manual*. 7th ed. New York, NY: Springer, 2010.

24. Lakhani SR, Ellis IO, Schnitt SJ, et al. *WHO classification of tumours of the breast*. World Health Organization classification of tumours. 4th ed. Lyon: IARC Press, 2012, pp.13–31.

25. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol* 2013; 24: 2206–2223.

26. Krag D, Weaver D, Ashikase T, et al. The sentinel node in breast cancer: a multicenter validation study. *N Engl J Med* 1998; 339: 941–946.

27. Zurrida S and Veronesi U. Milestones in breast cancer treatment. *Breast J* 2015; 21: 3–12.
28. Giuliano AE and Gangi A. Sentinel node biopsy and improved patient care. *Breast J* 2015; 21: 27–31.
29. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. *Breast Cancer Res Treat* 2006; 95: 279–293.
30. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. *N Engl J Med* 2003; 349: 546–553.
31. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol* 2010; 11: 927–933.
32. Kootstra JJ, Hoekstra-Weebers JE, Rietman JS, et al. A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection. *Ann Surg Oncol* 2010; 17: 2384–2394.
33. Goyal A, Newcombe RG, Chhabra A, et al. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase. *Breast Cancer Res Treat* 2006; 99: 203–208.
34. Hojo T, Nagao T, Kikuyama M, et al. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. *Breast* 2010; 19: 210–213.
35. He PS, Li F and Li GH. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review. *BMC Cancer* 2016; 16: 107.
36. Fattahi AS, Tavassoli A, Rohbakhshfar O, et al. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery? *J Res Med Sci* 2014; 19: 918–922.
37. Liu Y, Truini C and Ariyan S. A randomized study comparing the effectiveness of methylene blue dye with lymphazurin blue dye in sentinel lymph node biopsy for the treatment of cutaneous melanoma. *Ann Surg Oncol* 2008; 15: 2412–2417.
38. Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer: implications for use in pregnancy. *Am J Surg* 2011; 201: 70–75.
39. Li J, Chen X, Qi M, et al. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. *PLoS One* 2018; 30: 1–18.
40. Coromilas EJ, Wright JD, Huang Y, et al. Axillary evaluation and lymphedema in women with ductal carcinoma in situ. *Breast Cancer Res Treat* 2016; 158: 373–384.
41. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2014; 32: 1365–1383.
42. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. *J Clin Oncol* 2005; 23: 7703–7720.
43. Han C, Yang L and Zuo W. A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer. *Chin J Cancer Res* 2016; 28: 370–376.
44. Canavesel G, Catturich A, Vecchiol C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer: results of randomized trial. *Ann Oncol* 2005; 23: 7703–7720.
45. Han C, Yang L and Zuo W. A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer. *Chin J Cancer Res* 2016; 28: 370–376.
46. Canavesel G, Catturich A, Vecchiol C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. *Ann Oncol* 2009; 20: 1001–1007.
47. Molland JG, Dias MM and Gillett DJ. Sentinel node biopsy in breast cancer: results of 103 cases. *Aust N Z J Surg* 2000; 70: 98–102.
48. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium
sulfur colloid and isosulfan blue dye. *Ann Surg* 2001; 233: 51–59.

47. Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false negative rate. *J Am Coll Surg* 2001; 192: 684–691.

48. Chok KS, Suen DT, Lim FM, et al. Factors affecting false-negative breast sentinel node biopsy in Chinese patients. *ANZ J Surg* 2007; 77: 866–869.

49. Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? *Cancer* 2008; 113: 30–37.

50. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. *Ann Surg Oncol* 2006; 13: 491–500.

51. McCarter MD, Yeung H, Fey J, et al. The breast cancer patient with multiple sentinel nodes: when to stop? *J Am Coll Surg* 2001; 192: 692–697.

52. Cox CE, Pendas S, Cox JM, et al. Guidelines for the sentinel node biopsy and lymphatic of patients with breast cancer. *Ann Surg* 1998; 227: 645–653.

53. Snider H, Dowlatshahi K, Fan M, et al. Sentinel node biopsy in the staging of breast cancer. *Am J Surg* 1998; 176: 305–310.